About
ELGAN Pharma is a clinical-stage neonatology-focused biotechnology company developing safe, tailored therapies to address medical problems and developmental difficulties common in babies born very early.
The company has two leading clinical programs: ELGN-GI and ELGN-EYE. Both therapies address high unmet medical needs of preterm infants with no existing solutions to date.
ELGN-GI promotes a faster maturation of an infant’s intestines, allowing them to rapidly reach full enteral feeding and become independent from parenteral nutrition while minimizing serious complications and reducing burden and costs to healthcare systems. The product has completed several clinical trials, including a successful phase 3, and is currently starting a second phase 2.
ELGN-EYE is a local drug targeted at preventing vision impairment due to retinopathy of prematurity (ROP), a condition caused by the underdeveloped blood vessels in the eyes of premature babies at the time of birth. ROP is the leading cause of blindness in children worldwide. A phase 1 study of the product was successfully concluded and a phase 2 is currently launching.
Funding history · 2 rounds · $7.5M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is ELGAN Pharma's primary focus?
- ELGAN Pharma is a clinical-stage neonatology-focused biotechnology company developing therapies for medical problems and developmental difficulties in premature babies.
- What are ELGAN Pharma's two main clinical programs?
- ELGAN Pharma has two leading clinical programs: ELGN-GI, which promotes faster maturation of infant intestines, and ELGN-EYE, a local drug for preventing vision impairment due to retinopathy of prematurity (ROP).
- What is the current clinical trial status of ELGN-GI?
- ELGN-GI has completed several clinical trials, including a successful Phase 3 study, and is currently starting a second Phase 2 study.
- What is the current clinical trial status of ELGN-EYE?
- ELGN-EYE successfully concluded a Phase 1 study and is currently launching a Phase 2 study.
- When was ELGAN Pharma founded?
- ELGAN Pharma was founded in May 2018.
- What was ELGAN Pharma's first funding round?
- In July 2020, ELGAN Pharma raised $5,000,000 in a Seed round, with NGT3 as a lead investor.
- When did ELGAN Pharma receive its Series A funding?
- ELGAN Pharma received Series A funding in August 2022, with NGT HealthCare II among the investors.
- What grant did ELGAN Pharma receive in 2023?
- In July 2023, ELGAN Pharma received a grant of $2,500,000 from the IIA.
- What was a significant development for ELGAN Pharma in June 2025?
- In June 2025, ELGAN Pharma and Chiesi Group announced that the first infants were dosed in a Phase 3 study of ELGN-2112 for the treatment of intestinal malabsorption in preterm infants.